Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Entheon Biomedical Corp ENTBF


Primary Symbol: C.ENBI

Entheon Biomedical Corp. is a Canada-based biotechnology research and development company. The Company is focused on treating addiction and substance-use disorders.

Recent & Breaking News (CSE:ENBI)

Entheon Biomedical (CSE:ENBI) subsidiary launches psychedelics genetic test kit in the U.S.

Julia Kennedy  June 10, 2021

Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US

Newsfile June 10, 2021

Entheon Biomedical (CSE:ENBI) announces DMT drug supply agreement with Ofichem Group

Brieanna McCutcheon  May 18, 2021

Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

Newsfile May 18, 2021

Entheon Biomedical (CSE:ENBI) provides update on operations and strategic initiatives

Julia Kennedy  May 14, 2021

Entheon Biomedical Corp. Provides Corporate Update

Newsfile May 14, 2021

Entheon Biomedical Corp. Announces Participation in the Q2 Virtual Investor Summit

Newsfile May 11, 2021

Entheon Biomedical (CSE:ENBI) lists on the OTCQB Venture Market

John Ballem  May 5, 2021

Entheon Biomedical Lists on OTCQB Venture Market

Newsfile May 5, 2021

Entheon Biomedical Corp. (CSE:ENBI) launches HaluGen’s Psychedelics Genetic Test

Brieanna McCutcheon  April 6, 2021

Entheon Biomedical Corp. Launches HaluGen's Psychedelics Genetic Test

Newsfile April 6, 2021

March Psychedelic Capital Investigates Ethical IP and Financial Instruments

Newsfile March 30, 2021

Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs

Newsfile March 3, 2021

Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences

Newsfile February 24, 2021

Entheon Biomedical Announces Ethics Approval for In Vivo DMT Study

Newsfile February 22, 2021

Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development

Newsfile February 16, 2021

Entheon Biomedical Hires ClearTV Executive as VP of Digital Experience Entertainment Veteran Jonna Birgans to Oversee Digital and VR Content Development

Newsfile February 4, 2021

Entheon Biomedical Provides Update on Centre for Human Drug Research License Amendments

Newsfile February 2, 2021

The First Psychedelic ETF is Expected to Launch on January 27, 2021

Livemoney January 25, 2021

Entheon Biomedical to be Included in First North American Psychedelic ETF

Newsfile January 22, 2021